Market Place
Sourcing Support
Immune-Onc Doses 1st Patient In IO-108 Ph 1b/2 Liver Study With Roche
27 Feb 2025 //
BUSINESSWIRE
Immune-Onc Presents Promising IO-202 Data in CMML Patients at ASH
09 Dec 2024 //
BUSINESSWIRE
Immune-Onc Presents Positive IO-202 Data In CMML At EHA 2024
14 Jun 2024 //
BUSINESSWIRE
Immune-Onc Presents IO-202 CMML Data At EHA 2024 Congress
14 May 2024 //
BUSINESSWIRE
Immune-Onc Announces Orphan Drug Designation Granted by US FDA for IO-202
21 Feb 2024 //
BUSINESSWIRE
Immune-Onc Therapeutics Announces Trial Collaboration to Evaluate IO-108
20 Feb 2024 //
BUSINESSWIRE
Immune-Onc Presents IO-202 PhI Data in Patients with Relapsed or Refractory AML
07 Jun 2023 //
BUSINESSWIRE
Immune-Onc to Present Encouraging Phase 1 Data for IO-108 at AACR Meeting 2023
14 Apr 2023 //
BUSINESSWIRE
Immune-Onc Announces IO-108 Phase I Trial Results Selected for Presentation
14 Mar 2023 //
BUSINESSWIRE
Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology
03 Mar 2023 //
BUSINESSWIRE
Immune-Onc Therapeutics Announces Close of Series B Extension Financing
05 Jan 2023 //
BUSINESSWIRE
Immune-Onc to Present Trial in Progress Poster for Phase 1 Study of IO-202
10 Nov 2022 //
BUSINESSWIRE
Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors
08 Nov 2022 //
BUSINESSWIRE
Immune-Onc Initiates Expansion Cohorts for IO-108 & Agreement with Regeneron
17 Oct 2022 //
BUSINESSWIRE
Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China
10 Oct 2022 //
BUSINESSWIRE
Immune-Onc Appoints Christopher Whitmore as CFO and Provides Progress Update
14 Jul 2022 //
BUSINESSWIRE
Immune-Onc Announces Selection of IO-106 Targeting LAIR1
20 Apr 2022 //
BUSINESSWIRE
Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium
19 Apr 2022 //
BUSINESSWIRE
Immune-Onc initiates subject dosing in Phase I solid tumour therapy trial
13 Apr 2022 //
CLINICALTRIALSARENA
Immune-Onc Begins Dosing in Phase 1 Trial of IO-202 in Advanced Solid Tumors
12 Apr 2022 //
BUSINESSWIRE
Immune-Onc Therapeutics Makes Two Presentations of IO-108 at the AACR
08 Apr 2022 //
BUSINESSWIRE
Immune-Onc Announces Poster Presentations for IO-108 at AACR 2022
09 Mar 2022 //
BUSINESSWIRE
Immune-Onc Tx to Participate in two Healthcare Conference
28 Feb 2022 //
BUSINESSWIRE
Immune-Onc Therapeutics Receives FDA FTD for IO-202 in AML
17 Feb 2022 //
BUSINESSWIRE
FDA Clears Immune-Onc`s IND to Initiate Trial of IO-202 in Advanced Solid Tumors
31 Jan 2022 //
BUSINESSWIRE
Immune-Onc to Present at Evercore ISI 4th Annual HealthCONx Conference
22 Nov 2021 //
BUSINESSWIRE
Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial
13 Oct 2021 //
BUSINESSWIRE
Immune-Onc Begins Dosing in Phase 1 Trial Evaluating IO-108 in Solid Tumors
13 Oct 2021 //
BUSINESSWIRE
Immune-Onc Therapeutics Announces FDA Clearance of IND Application of IO-108
12 Aug 2021 //
BUSINESSWIRE
Immune-Onc Therapeutics Announces First Public Presentation of Data
09 Apr 2021 //
BUSINESSWIRE
Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing
30 Mar 2021 //
BUSINESSWIRE
Immune-Onc Announces $73 Million in Series B1 and B2 Financing
30 Mar 2021 //
BUSINESSWIRE
Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202
10 Nov 2020 //
ORG
Immune-Onc Therapeutics to Present Preclinical Data for IO-108
09 Nov 2020 //
BIOSPACE
Immune-Onc Therapeutics Announces beginning of Phase I Trial Evaluating IO-202
16 Sep 2020 //
BUSINESSWIRE
Immune-Onc Therapeutics Awarded $2.14 M National Cancer Institute SBIR Grant
04 Aug 2020 //
BUSINESSWIRE
